VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive the firm rounded out the second quarter with $21.3 million in cash and equivalents compared to $12 million in the same quarter a year ago. The company's now tested two independent cohorts of COVID-19 positive patients with quantitative nucleosome immunoassays and found that nucleosomes were “highly elevated” in plasma of severe COVID-19 patients relative to healthy control subjects. Reynolds says the data implies that Nu.Q could have strong prognostic potential.
VolitionRX progressing towards launch of first commercial products using Nu.Q platform
Quick facts: VolitionRx
Price: 4.01 USD
Market Cap: $193.27 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE